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Background
Imatinib (IM) inhibits the TK protein from chromosome
Philadelphia (Ph). However, less than 10% of IM-treated
patients become resistant. Second generation TK inhibi-
tors are on active clinical research aimed to overcome
most, but not all, important mutations.
Case report
A 61 year-old male was diagnosed on Sep/98 with CML
chronic phase, he was treated with hydroxiurea, interferon
and Ara-C. On July/01 the patient was on complete hema-
tological response (CHR), but Ph positive in karyotyping
(Ky) and fluorescence in-situ hybridization (FISH), there
were not additional abnormalities. Patient began IM treat-
ment, 400 mg/day. After 4 months of treatment, +der(22)
was detected, but the patient was still on CHR. On subse-
quent visits, the patient had an increased frequency of
chromosomal abnormalities, and after 2 years he lost
CHR, regardless of the increase IM dose and the concom-
itant use of Ara-C. The patient was included on a dasatinib
phase II protocol. 2 weeks after he had a profound cytope-
nia and 2 months after had CHR. Table 1 shows clinical
and hematological and Ky and FISH follow-up.
Conclusion
Additional abnormalities found on Ky and FISH could
preceed treatment failure. Molecular monitoring is
required to guide treatment decisions. The role of second
generation TK inhibitors needs to be defined.
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Sample Date Ky FISH Treatment & clinical condition
1 Jul/01 Only Ph Only Ph 35% Began IM 400 mg/d CHR
2 Nov/01 Ph plus double Ph Not enough material IM 400 mg/d CHR
3 Jan/02 No growth Only Ph 26% IM 400 mg/d CHR
4 Sep/02 Hipodiploid plus Ph Only Ph 22%
Clone BCR amplified without Ph 3%
Clone ABL amplified and Ph 5%
IM 400 mg/d Leucocytosis
5 Jun/03 Only Ph Only Ph = 28%
Clone BCR amplified without Ph = 1%
Clone ABL and/or BCR amplified with Ph = 28%
Clone ABL and/or BCR amplified and double Ph = 51%
Clone ABL and BCR amplified with triple Ph = 11%
Clone ABL lost with Ph = 5%
IM 600 mg/d
6 Nov/03 Ph plus lost Y, marker chromosome, trisomy chr 19, double 
Ph and trisomy chr 8.
Only Ph = 4%
Clone ABL amplified without Ph = 1%
Clone ABL and/or BCR amplified with Ph = 18%
Clone ABL and/or BCR amplified with double Ph = 74%
Clone ABL and BCR amplified with triple PH = 1%
Trisomy chr 8 = 72%
IM 600 mg + Ara-C
7 Jul/04 No growth Only Ph = 44%
Clone ABL amplified with Ph = 6%
Clone ABL and/or BCR amplified with double Ph = 17%
IM 800 mg/d
sample Jan/ 05 Began with dasatinib
8 Dec/05 No growth Only Ph = 18% DasatinibPage 2 of 2
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